Description
Retatrutide, also known as LY3437943, is an engineered peptide designed to activate the GIP, GLP-1 and glucagon receptors. It remains investigational and has not been approved by a medicines regulator for public use.
The molecule is studied in receptor-pharmacology, metabolic and clinical-development programmes. Auren supplies this listing only as a laboratory research material; the page does not describe a dose, route, schedule or expected outcome in a person.



Reviews
There are no reviews yet.